相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth. University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]
Antonio Abbate et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Targeting Interleukin-1 in Heart Disease
Benjamin W. Van Tassell et al.
CIRCULATION (2013)
Heart Disease and Stroke Statistics-2013 Update A Report From the American Heart Association
Alan S. Go et al.
CIRCULATION (2013)
Interleukin-1 blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse
Stefano Toldo et al.
EXPERIMENTAL PHYSIOLOGY (2013)
The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β
Nathan A. Bracey et al.
EXPERIMENTAL PHYSIOLOGY (2013)
Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events
Antonio Abbate et al.
BIODRUGS (2012)
Inflammatory Cytokines in Heart Failure: Mediators and Markers
Lars Gullestad et al.
CARDIOLOGY (2012)
Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the Mouse
Stefano Toldo et al.
CARDIOVASCULAR DRUGS AND THERAPY (2012)
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Charles A. Dinarello et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure
Benjamin W. Van Tassell et al.
PLOS ONE (2012)
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Paul M. Ridker et al.
AMERICAN HEART JOURNAL (2011)
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Charles A. Dinarello
BLOOD (2011)
Right Ventricular Dysfunction following Acute Myocardial Infarction in the Absence of Pulmonary Hypertension in the Mouse
Stefano Toldo et al.
PLOS ONE (2011)
Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)
Antonio Abbate et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse
Antonio Abbate et al.
EUROPEAN JOURNAL OF HEART FAILURE (2010)
Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity
Jinzhou Zhu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Increased Cytokine Production in Interleukin-18 Receptor α-deficient Cells Is Associated with Dysregulation of Suppressors of Cytokine Signaling
Claudia A. Nold-Petry et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Neutralization of Interleukin-18 Ameliorates Ischemia/Reperfusion-induced Myocardial Injury
Kaliyamurthi Venkatachalam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review
Jose Paulo Araujo et al.
JOURNAL OF CARDIAC FAILURE (2009)
Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling
Marcin Bujak et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction
Antonio Abbate et al.
CIRCULATION (2008)
The effect of daily administration of IL-18 on cardiac structure and function
A. Platis et al.
PERFUSION-UK (2008)
Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload
James T. Colston et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition
Raphaela Goldbach-Mansky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation
Ilona Gutcher et al.
NATURE IMMUNOLOGY (2006)
Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice
PR Woldbæk et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Differences in signaling pathways by IL-1β and IL-18
JK Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
ES Chung et al.
CIRCULATION (2003)
Increased circulating Interleukin-18 levels in centenarians with no signs of vascular disease:: another paradox of longevity?
S Gangemi et al.
EXPERIMENTAL GERONTOLOGY (2003)
Increased circulating interleukin-18 in patients with congestive heart failure
Y Naito et al.
HEART (2002)
Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction
CD Raeburn et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2002)
The epidemiological features of heart failure in developing countries: a review of the literature
GF Mendez et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2001)
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18
D Novick et al.
CYTOKINE (2001)
Circulating cytokines as mediators of fever
MG Netea et al.
CLINICAL INFECTIOUS DISEASES (2000)